Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Ciscom Corp. Strengthens Its Board of Directors with Addition of Two Experienced Industry Leaders (click to learn more) Silver North Options GDR Silver Project, Silvertip-Midway District, Yukon (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioCardia Inc BCDA

Healthcare Biotechnology
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and... see more

Recent & Breaking News (NDAQ:BCDA)

BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

Business Wire December 6, 2022

BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results

GlobeNewswire November 9, 2022

BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022

GlobeNewswire November 2, 2022

BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting

GlobeNewswire October 3, 2022

CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data to be Presented at Heart Failure Society of America Annual Meeting

GlobeNewswire September 14, 2022

BioCardia Announces Participation at H.C. Wainwright Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)

GlobeNewswire September 9, 2022

BioCardia to Participate in Cantor Fitzgerald's Cell and Genetic Medicines Conference

GlobeNewswire September 8, 2022

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

GlobeNewswire August 31, 2022

BioCardia Enters Agreement with BlueRock Therapeutics to Provide Enabling Catheter Biotherapeutic Delivery Product Candidates for BlueRock's Cell Therapy to Treat Heart Failure

GlobeNewswire August 24, 2022

BioCardia Reports Second Quarter 2022 Business Highlights And Financial Results

GlobeNewswire August 10, 2022

BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022

GlobeNewswire August 4, 2022

BioCardia Announces First Canadian Clinical Site for CardiAMP Cell Therapy Heart Failure Trial

GlobeNewswire August 1, 2022

BioCardia to Participate in Upcoming Heart and Pulmonary Therapy Development Symposia

GlobeNewswire July 12, 2022

BioCardia Announces US Patent on Imaging System for Targeting Cardiac Therapies

GlobeNewswire June 15, 2022

BioCardia Reports First Quarter 2022 Business Highlights and Financial Results

GlobeNewswire May 11, 2022

BioCardia to Host Q1 2022 Financial Results and Corporate Update Conference Call on May 11, 2022

GlobeNewswire May 4, 2022

BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19

GlobeNewswire April 12, 2022

BioCardia Reports 2021 Financial Results and Recent Business Highlights

GlobeNewswire March 29, 2022

BioCardia to Host 2021 Financial Results and Corporate Update Conference Call on March 29, 2022

GlobeNewswire March 24, 2022

BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure

GlobeNewswire March 22, 2022